Creative Touch Permanent Makeup and Aesthetics

Cortisol is the primary human glucocorticoid and a potent regulator of skin homeostasis. While vital for acute stress response, its chronic elevation, whether through systemic HPA-axis activation (stress/sleep deprivation) or local amplification via the 11β-HSD1 enzyme, is catastrophic for skin structure. Cortisol acts as a biological “brake,” suppressing collagen synthesis by up to 60%, inhibiting the production of barrier lipids ( ceramides), and delaying keratinocyte migration. In the clinic, high cortisol levels manifest as “thin” skin that is slow to heal and poorly responsive to stimulation, necessitating a “bypass” strategy through Polynucleotides or iPRF.

Cortisol is a steroid hormone produced by the zona fasciculata of the adrenal cortex, released in response to ACTH from the pituitary as the downstream effector of the hypothalamic-pituitary-adrenal (HPA) axis. ^[7] It is the primary glucocorticoid in humans, regulating glucose metabolism, immune activity, cardiovascular tone, and inflammatory response. In the context of acute, time-limited stress, cortisol is physiologically appropriate: it mobilises energy, suppresses inflammatory responses, and returns the organism to baseline when the stressor resolves. The skin effects that concern us clinically arise not from normal cortisol physiology but from two specific conditions: chronic systemic elevation, and the age-related increase in local cortisol production within skin tissue itself.

The Two Routes to Elevated Skin Cortisol

What makes cortisol particularly relevant to skin ageing – and this is not widely appreciated outside specialist endocrinology – is that there are two independent routes by which skin cells can be exposed to elevated cortisol, and only one of them requires the person to be stressed.

Systemic elevation via HPA axis activation is the familiar route: chronic psychological stress, sleep deprivation, caloric restriction, and perceived threat all activate the HPA axis, increasing circulating cortisol. That elevated systemic cortisol reaches skin cells through normal perfusion. ^[3]

Local amplification via 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the less-discussed route, and the one with direct implications for intrinsic skin ageing. 11β-HSD1 is an enzyme expressed in both epidermal keratinocytes and dermal fibroblasts that converts inactive cortisone into active cortisol within the cell. ^[12] Critically, 11β-HSD1 activity increases with age in human skin, both in keratinocytes and fibroblasts , meaning that aged skin cells are locally producing more active cortisol from available cortisone substrate, independently of systemic stress levels. ^[11] In mouse models, genetic knockout of 11β-HSD1 prevents age-induced dermal atrophy and disorganised collagen architecture and increases collagen density. This is direct experimental evidence that local cortisol activation by 11β-HSD1 is a mechanistic driver of intrinsic ageing rather than merely a correlate. ^[11]

Psychological stress adds a third layer: PS upregulates 11β-HSD1 expression in keratinocytes, meaning stress both raises systemic cortisol and amplifies the local conversion mechanism simultaneously – a compounding effect. ^[4]

The Dual Routes of Cortisol Exposure

Cortisol and Dermal Collagen

The collagen effects of cortisol are well-characterised and operate at multiple points in the synthesis and maintenance pathway. Glucocorticoid excess, whether exogenous or endogenous, reduces type I collagen expression in dermal fibroblasts by approximately 54–59%, confirmed in primary human dermal fibroblast cultures. ^[2] The mechanism involves inhibition of rate-limiting steps in both collagen biosynthesis and post-translational processing, confirmed in studies of physiological cortisol concentrations applied to human dermal fibroblasts in culture. ^[11] The glucocorticoid receptor (GR) activation in fibroblasts suppresses p38 MAPK phosphorylation, a signalling pathway that positively regulates collagen synthesis, whilst simultaneously promoting PI3K/AKT/mTOR-driven cellular senescence. ^[8]

The result in chronically elevated or locally amplified cortisol conditions is that dermal fibroblasts simultaneously produce less collagen, process what they do produce less efficiently, and accumulate senescence faster – a convergence of three independent deficits that reinforces the structural collagen loss described in the Collagen and Fibroblast entities. The clinical presentation in Cushing’s syndrome, where circulating glucocorticoid excess is pathologically extreme, provides a human model of severe cortisol-driven skin atrophy that makes mechanistic relationships visible at scale: skin becomes thin, fragile, slow to heal, and prone to striae as collagen production collapses.

Cortisol’s “Triple Deficit” in the Dermis

Cortisol and the Epidermal Barrier

Cortisol’s barrier effects operate through two distinct mechanisms that are often conflated but belong to different parts of the barrier production chain.

Keratinocyte differentiation inhibition – elevated cortisol reduces keratinocyte proliferation and differentiation, impairing the production of late differentiation markers including loricrin (a key cornified envelope protein) and the processing of profilaggrin into filaggrin. ^[4] Since filaggrin content directly determines NMF production and contributes to the acid mantle, cortisol-driven differentiation impairment has downstream consequences for both corneocyte quality and stratum corneum pH – the same acid mantle dependency described in the Filaggrin and Stratum Corneum entities, now reached through a hormonal rather than inflammatory route.

Barrier lipid synthesis inhibition – cortisol suppresses the synthesis of epidermal lipids including ceramides and cholesterol, reducing lamellar body production and the extracellular lipid matrix of the stratum corneum. ^[10] Studies using topical glucocorticoid-treated animal models identified lipid synthesis inhibition as the key mechanism for stress-induced barrier abnormalities, distinct from and additive to the differentiation impairment. ^[3]

Together, these two mechanisms produce measurable barrier deterioration: elevated stratum corneum cortisol correlates directly with increased basal TEWL and reduced SC integrity in human subjects under psychological stress, with stratum corneum cortisol levels measurable directly from tape-stripped samples. ^[4] Skin surface pH also increases under elevated cortisol conditions, impairing the acid-dependent ceramide-processing enzymes that the Stratum Corneum entity describes – a third route through which cortisol disrupts barrier function independently of its direct synthesis suppression.

Cortisol and Barrier Recovery Delay

Beyond the chronic suppression effects, cortisol measurably delays the recovery of barrier function after acute disruption. In human clinical studies, an interview stress protocol causing delayed barrier recovery was associated with simultaneous increases in plasma cortisol, norepinephrine, and IL-1β. ^[1] Laboratory stressor paradigms produce consistent barrier recovery delays in tape-stripping models – the barrier disruption is the same; it is the cortisol-elevated repair environment that slows restoration. ^[5] The mechanism involves cortisol-driven impairment of keratinocyte migration – a direct effect on wound re-epithelialisation that extends beyond barrier maintenance to active repair. ^[9]

This barrier recovery delay has a direct implication for professional treatment protocols at Creative Touch. Treatments that depend on controlled wound-healing cascades such as RF microneedling, thulium laser, microneedling, iPRF, deliver their benefits through a healing response. In clients where cortisol is chronically elevated or locally amplified through age-related 11β-HSD1 upregulation, the healing response those treatments depend on is operating in a suppressed environment. Recovery timelines extend, fibroblast activation is attenuated, and collagen synthesis outcomes are reduced relative to what the treatment mechanism alone would produce in a well-regulated hormonal environment.